T1001	food 18 24	Orange
T1002	food 29 40	apple juice
T1004	pharmacokinetics 60 81	plasma concentrations
T1006	food 196 208	orange juice
T1007	food 213 224	apple juice
T1008	pharmacokinetics 232 248	pharmacokinetics
T1009	drug 273 282	aliskiren
T10010	studyType 289 315	randomized crossover study
T10011	population 317 338	12 healthy volunteers
T10012	mode 339 347	ingested
T10013	dosage 348 354	200 ml
T10014	food 358 370	orange juice
T10015	food 372 383	apple juice
T10016	food 387 392	water
T10017	frequency 393 410	three times daily
T10018	mode 438 446	ingested
T10019	frequency 449 455	single
T10020	dosage 456 462	150-mg
T10024	food 625 636	apple juice
T10025	interaction 637 644	reduced
T10026	drug 645 654	aliskiren
T10027	pharmacokinetics 655 681	peak plasma concentrations
T10028	value 722 725	84%
T10029	drug 786 795	aliskiren
T10030	pharmacokinetics 796 820	concentration-time curve
T10031	pharmacokinetics 822 825	AUC
T10032	value 867 870	63%
T10033	pharmacokinetics 952 973	elimination half-life
T10034	pharmacokinetics 977 992	renal clearance
T10035	interaction 998 1007	decreases
T10036	drug 1011 1020	aliskiren
T10037	pharmacokinetics 1021 1024	AUC
T10038	food 1028 1034	orange
T10039	food 1039 1050	apple juice
T10040	drug 1067 1076	aliskiren
T10041	pharmacokinetics 1077 1080	AUC
T10042	food 1092 1097	water
T10043	value 1152 1163	87% and 67%
T10044	drug 1185 1194	aliskiren
T10045	food 1206 1218	orange juice
T10046	food 1223 1234	apple juice
T10047	food 1273 1278	water
T10048	food 1297 1309	Orange juice
T10049	food 1314 1325	apple juice
T10050	interaction 1334 1340	reduce
T10051	pharmacokinetics 1345 1366	plasma concentrations
T10052	drug 1398 1407	aliskiren
T10053	drug 1506 1515	aliskiren
T10054	food 1521 1527	orange
T10055	food 1531 1542	apple juice
T10058	duration 411 421	for 5 days
T10061	food 614 620	Orange
T10062	value 685 688	80%
T10063	value 697 705	63%, 89%
T10064	value 734 742	72%, 91%
T10065	pharmacokinetics 764 785	area under the plasma
T10067	value 830 835	62% (
T10068	value 842 851	47%, 72%,
T10069	value 879 888	46%, 74%,
T10070	interaction 923 944	no significant effect
T10072	drugEffect 1371 1394	renin-inhibiting effect
T10073	enzyme 1436 1443	OATP2B1
T10074	pharmacokinetics 97 106	substrate
T10057	mealTime 1484 1502	Concomitant intake
T2005	enzyme 89 96	OATP2B1
T20021	drug 489 498	aliskiren
T20056	drug 107 116	aliskiren
T20059	drug 471 480	aliskiren
T20060	pharmacokinetics 544 564	excretion into urine
T2003	interaction 41 55	greatly reduce
T20023	parameter 580 601	plasma renin activity
T20065	parameter 1126 1147	Plasma renin activity
T20072	interaction 1421 1431	inhibiting
T20057	other 253 269	pharmacodynamics
T20071	mode 1496 1502	intake
T2	pharmacokinetics 482 488;499 513	Plasma concentrations
R1	decrease_pharmacokinetic_parameter Arg1:T10061 Arg2:T10026	
R2	decrease_pharmacokinetic_parameter Arg1:T10024 Arg2:T10026	
R3	decrease_pharmacokinetic_parameter Arg1:T10038 Arg2:T10036	
R4	decrease_pharmacokinetic_parameter Arg1:T10039 Arg2:T10036	
R5	physiological_effect_antagonism Arg1:T10045 Arg2:T10044	
R6	physiological_effect_antagonism Arg1:T10046 Arg2:T10044	
R7	decrease_pharmacokinetic_parameter Arg1:T10048 Arg2:T10052	
R8	decrease_pharmacokinetic_parameter Arg1:T10049 Arg2:T10052	
R9	decrease_pharmacokinetic_parameter Arg1:T10061 Arg2:T10029	
R10	decrease_pharmacokinetic_parameter Arg1:T10024 Arg2:T10029	
R11	absorption_decrease Arg1:T10049 Arg2:T10052	
R12	absorption_decrease Arg1:T10049 Arg2:T10052	
#1	AnnotatorNotes R11	Ã  nuancer par le terme "probably"
